Concord Asset Management LLC VA Purchases Shares of 13,211 Pfizer Inc. (NYSE:PFE)

Concord Asset Management LLC VA bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 13,211 shares of the biopharmaceutical company’s stock, valued at approximately $350,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $26,000. Gladius Capital Management LP boosted its position in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares during the last quarter. Quarry LP acquired a new stake in Pfizer in the second quarter valued at $31,000. Teachers Insurance & Annuity Association of America bought a new position in Pfizer during the third quarter worth $35,000. Finally, Joseph Group Capital Management lifted its stake in shares of Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 771 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Citigroup reduced their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Truist Financial decreased their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Down 1.5 %

Shares of Pfizer stock opened at $26.51 on Friday. The stock has a market capitalization of $150.20 billion, a PE ratio of 35.82, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a 50-day simple moving average of $26.27 and a two-hundred day simple moving average of $27.87. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the firm earned ($0.17) EPS. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.49%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is currently 232.44%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.